More than relevant. It's a key read if you're following the bouncing ball towards a new potency assay paradigm allowing MSC use in human cellular treatments, even if the draft pulls up short a bit - I guess they're keen for submissions? Note that when ratified it will supercede the 2011 document. Covers more than MSCs of course. Notable time to observe imminent commercialisation of medical biology exploring inflammatory/immunity modulation using pluripotent cells - recruiting powerful archaic systems to mediate repair and paracrine profile when fundamental survival systems go wrong in response to other cellular behaviour going wrong (ie. in respect of transplants + SR-aGVHD). v.cool.stuff.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707740/
Ann: Update on Institutional Placement and Entitlement Offer, page-460
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 86854 | 7 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |